18F-FPIA in Glioblastoma (FAM-GBM)
Research type
Research Study
Full title
An observational study to determine changes in 18F-fluoropivalate-PET during postoperative chemoradiotherapy for patients with primary glioblastoma multiforme
IRAS ID
262574
Contact name
Matthew Williams
Contact email
Sponsor organisation
Imperial College London
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Tumours have increased energy demands to allow for their rapid growth compared to healthy cells. Glucose is the main source of energy in healthy brain, however it has been shown that brain tumour cells have can create energy from an alternative pathway which involves fatty acid metabolism. We can measure this fatty acid metabolism using a new scan. We plan to scan patients over the course of their treatment to see whether changes in fatty acid metabolism correlate with whether the patient responds to treatment.
This study uses a PET-CT scanner (Positron Emission Tomography combined Computed Tomography), along with a very small amount of an injected, radioactive substance called a “tracer”. In this study, a tracer called 18Ffluoro- 2,2 dimethylpropionic acid (18F-FPIA) will be used. The PET-CT scanner can detect the tracer in your brain and produce images from the radioactivity taken in by tumour cells. We believe that as brain tumour cells undergo fatty acid metabolism to create energy we can measure how much of this process is going on based on the amount of tracer that the brain tumour cells take in. Quantification of fatty acid metablolism using 18F PET-CT in glioblastoma will be performed at three time point during the patients treatment, 1. Before the patient undergoes chemoradiotherapy 2. Mid chemoradiotherapy and 3. post chemoradiotherapy.
REC name
London - Surrey Research Ethics Committee
REC reference
21/LO/0636
Date of REC Opinion
25 Jan 2022
REC opinion
Further Information Favourable Opinion